Phase II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy

J. M. Denefrio; C. L. Vogel

Phase II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy

J. M. Denefrio, C. L. Vogel

Medicine

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

In the present dose and schedule, the authors found hexamethylmelamine to be ineffective in the management of metastatic breast cancer already refractory to standard chemotherapy and hormonal therapeutic approaches in 19 cases.

Original language	English (US)
Pages (from-to)	173-175
Number of pages	3
Journal	Cancer Treatment Reports
Volume	62
Issue number	1
State	Published - Jan 1 1978

ASJC Scopus subject areas

Oncology
Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy'. Together they form a unique fingerprint.

Cite this

@article{2ce50eac7324434e91da588f132e1626,

title = "Phase II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy",

abstract = "In the present dose and schedule, the authors found hexamethylmelamine to be ineffective in the management of metastatic breast cancer already refractory to standard chemotherapy and hormonal therapeutic approaches in 19 cases.",

author = "Denefrio, {J. M.} and Vogel, {C. L.}",

year = "1978",

month = jan,

day = "1",

language = "English (US)",

volume = "62",

pages = "173--175",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Phase II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy

AU - Denefrio, J. M.

AU - Vogel, C. L.

PY - 1978/1/1

Y1 - 1978/1/1

N2 - In the present dose and schedule, the authors found hexamethylmelamine to be ineffective in the management of metastatic breast cancer already refractory to standard chemotherapy and hormonal therapeutic approaches in 19 cases.

AB - In the present dose and schedule, the authors found hexamethylmelamine to be ineffective in the management of metastatic breast cancer already refractory to standard chemotherapy and hormonal therapeutic approaches in 19 cases.

UR - http://www.scopus.com/inward/record.url?scp=0017904268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017904268&partnerID=8YFLogxK

M3 - Article

C2 - 414835

AN - SCOPUS:0017904268

VL - 62

SP - 173

EP - 175

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 1

ER -

Phase II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy

Abstract

ASJC Scopus subject areas

Other files and links

Cite this